[In vivo antitumor activities of polyethylene glycol modified recombinant interleukin 2 (PEG-rIL-2) against murine hepatoma].
Recombinant human interleukin 2 purified from Escherichia coli has a limited solubility at neutral pH and a short circulatory half-life. This recombinant interleukin 2 was chemically modified by an active ester of polyethylene glycol. The modified interleukin 2 presented in this paper showed an increased antitumor potency in murine hepatoma model, which included prolonging the survival of tumor-bearing mice (from 16.0 +/- 1.8 d to 20.2 +/- 0.9 d, P < 0.01), reducing the lung metastases of hepatoma (from 14.0 +/- 0.7 nodules to 7.5 +/- 1.8 nodules, P < 0.01) and inhibiting the subcutaneous tumor growth (P < 0.01). The results demonstrate that the polyethylene glycol modified interleukin 2 has a higher antitumor activity than unmodified interleukin 2 in vivo and is a potential immunological agent in the adoptive immunotherapy of hepatoma.
Feng
X S
XS
Liver Cancer Institute, Shanghai Medical University.
D000818:Animals; D005260:Female; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008114:Liver Neoplasms, Experimental / Q000628:therapy*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011092:Polyethylene Glycols
D007376:Interleukin-2; C067245:interleukin-2, polyethylene glycol-modified; D011092:Polyethylene Glycols